Danuglipron (PF-06882961) is an oral non-peptide small molecule glucagon-like peptide-1 (GLP-1) receptor agonist developed by Pfizer. Like orforglipron, it represents the emerging class of small molecule GLP-1R agonists that aim to provide the metabolic benefits of injectable GLP-1 peptide agonists in a convenient oral pill format.

Overview

Danuglipron emerged from Pfizer's medicinal chemistry program aimed at creating orally bioavailable small molecule GLP-1 receptor agonists. The compound was identified through structure-guided optimization and is structurally distinct from both endogenous GLP-1 and from Eli Lilly's orforglipron. In Phase 2b studies, danuglipron demonstrated dose-dependent weight loss and glycemic improvements, validating the small molecule GLP-1R agonist approach.

However, the development path for danuglipron has been challenging. The immediate-release twice-daily formulation showed meaningful efficacy but was associated with high rates of gastrointestinal adverse events, particularly nausea and vomiting, that led to substantial dropout rates at higher doses. In late 2023, Pfizer announced it would discontinue development of the twice-daily formulation and instead focus on a modified-release (MR) once-daily formulation designed to reduce peak plasma concentrations and thereby improve GI tolerability while maintaining efficacy through sustained GLP-1R engagement.

Mechanism of Action

Danuglipron activates the GLP-1 receptor through direct binding to produce downstream metabolic effects:

GLP-1 Receptor Agonism: Danuglipron is a full agonist at the human GLP-1 receptor, binding at a site that partially overlaps with the orthosteric peptide binding domain but also engages unique small molecule-specific contacts within the transmembrane domain. Cryo-EM structural studies have elucidated its binding mode. This results in Gs protein activation and intracellular cAMP accumulation that drives insulin secretion.

Glucose-Dependent Insulin Secretion: By activating GLP-1 receptors on pancreatic beta cells, danuglipron stimulates insulin release only when blood glucose levels are elevated, minimizing the risk of hypoglycemia. This glucose-dependent mechanism is a hallmark of the GLP-1R agonist class.

Glucagon Suppression: Danuglipron suppresses inappropriate glucagon secretion from pancreatic alpha cells, reducing hepatic glucose production and contributing to improved fasting and postprandial glucose levels.

Central Appetite Regulation: Like other GLP-1R agonists, danuglipron acts on GLP-1 receptors in the hypothalamus and hindbrain to reduce appetite, food intake, and body weight. Central penetration of the small molecule contributes to these anorectic effects.

Gastric Motility: Danuglipron delays gastric emptying through vagal signaling pathways, contributing to postprandial glucose control and promoting satiety.

Beta-Arrestin Recruitment: Structural and pharmacological studies indicate that danuglipron has a distinct signaling bias compared to native GLP-1, with differences in beta-arrestin-1 and beta-arrestin-2 recruitment that may influence receptor internalization, desensitization, and ultimately the therapeutic profile.

Reconstitution Calculator

Research

Safety Profile

The safety profile of danuglipron is characterized by dose-dependent gastrointestinal adverse events. In Phase 2b trials with the immediate-release formulation, nausea occurred in 40-73% of participants at therapeutic doses (vs. 20% placebo), vomiting in 17-47%, and diarrhea in 15-33%. These rates are notably higher than those reported for injectable GLP-1R agonists or orforglipron, likely reflecting the rapid absorption and high peak concentrations of the immediate-release formulation. Discontinuation due to adverse events was a significant concern, reaching approximately 50% at the 120 mg BID dose. No pancreatitis, thyroid C-cell abnormalities, or medullary thyroid carcinoma signals were identified. Heart rate increases of 2-5 bpm were observed, consistent with the GLP-1R agonist class. Hepatic safety signals were not detected in clinical trials.

Clinical Research Protocols

• Phase 2b (IR, obesity): Doses of 10 mg, 40 mg, 80 mg, and 120 mg twice daily evaluated over 32 weeks with dose-escalation schedules to manage GI tolerability.
• Phase 1 (MR formulation): Once-daily modified-release formulation evaluated in healthy volunteers for pharmacokinetics and tolerability.
• Phase 2b (MR formulation): Initiated mid-2024 evaluating once-daily MR danuglipron at multiple dose levels in patients with obesity. Results anticipated 2025.
• Dose escalation (IR): Gradual titration over 4-8 weeks to target doses.
• Administration (IR): Twice daily with food. MR formulation designed for once-daily dosing.

Subpopulation Research

• Adults with obesity (BMI >=30): Phase 2b IR data showed approximately 6.9 kg weight loss with 120 mg BID at 32 weeks, but with high discontinuation rates.
• Type 2 diabetes: Dose-dependent HbA1c reductions of up to 1.16% from baseline demonstrated efficacy in glycemic control.
• Japanese population: Phase 1 studies conducted in Japanese subjects showed broadly similar pharmacokinetics to Western populations.
• Hepatic impairment: Dedicated hepatic impairment studies evaluating impact on danuglipron exposure.
• Elderly: Age-specific subgroup analyses from Phase 2b trials did not reveal clinically meaningful differences in efficacy or safety in older adults.

Pharmacokinetic Profile

Ongoing & Future Research

• Modified-release Phase 2b/3: The MR once-daily formulation is Pfizer's primary development path, with Phase 2b data expected in 2025. Success would lead to Phase 3 registration trials.
• GI tolerability optimization: The MR formulation is specifically designed to address the high GI adverse event rates and discontinuation observed with the IR formulation. Smoothing the pharmacokinetic profile is expected to significantly improve tolerability.
• Combination strategies: Pfizer may explore combinations with other metabolic agents if the MR monotherapy program succeeds.
• Head-to-head studies: If MR danuglipron progresses to Phase 3, comparator studies against injectable GLP-1R agonists or orforglipron may be conducted.
• Cardiovascular outcomes: A dedicated CVOT would be required for regulatory approval if seeking a cardiovascular risk reduction indication.
• MASH/NASH: Potential hepatic indications based on the class effect of GLP-1R agonists on liver fat and inflammation.